Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

Drug Pricing 'Deeper Dive' Planned By Senate Cmte. As Industry Avoids First Blood

Hearings in July and the fall will follow, but if the first session was any indication, industry doesn't have anything to worry about.

Policy Pricing Debate Legislation

Latest From Pricing Debate

FDA Getting Reg Slashing Directive In Trump Executive Order

Draft order wants "comprehensive review" to find regulations that that "unnecessarily increases expenses" for patients, researchers, and manufacturers.

Pricing Debate Generic Drugs

Trump Exec Order On Drug Costs: Seeking To Balance Access, Innovation

Draft version of order signals a focus on insurance benefit design, accelerating drug approvals and de-regulation.

Pricing Debate Market Access

Complex Generics May Be Part Of White House Drug Pricing Response

Document that appears to be fueling upcoming executive order includes ideas for relaxing FDA standards for complex generic approval, which may be one way of creating pressure to lower prices.

Generic Drugs Pricing Debate

Pricing Deregulation: 340B Pharmacy Policy, Medicaid Payment Rules May Be Withdrawn

Trump administration's drug pricing action plan considers withdrawing guidance and whole or parts of rules that biopharma has opposed.

Pricing Debate Medicaid

FDA's Generic Policy Initiative Includes Choose-Your-Own-Agenda Meeting

US agency is seeking feedback from interested stakeholders about administrative steps it can take to better promote generic competition; July 18 meeting will involve only presentations from the public.

Generic Drugs Pricing Debate

Trump Administration's Pharma-Friendly Pricing Proposals Prompt Pushback

As work on policy development and executive orders continues, critics implore Trump to return to his "getting away with murder" roots.

Pricing Debate Market Access

Rx Pricing: Adversaries Search For Common Ground On Value-Based Contracts

Celgene, Express Scripts, and Aetna discuss need for shared accountability, data sharing and value assessment at DIA meeting.

Pricing Debate Private Payers

ADA 2017: Outlook For New Longer Acting Insulins Amid US Pricing Sensitivity

The high cost of basal insulins in the US has drawn a fair amount of scrutiny recently, placing increased pressure on new longer acting insulins to demonstrate superior cost-efficacy compared to standard of care Lantus to gain preferential formulary placement. This has become significantly more difficult with the US launch of Lilly's biosimilar, Basaglar.

Pricing Debate Pricing Strategies

Saunders: Industry Must Act Before We Lose Champions For Innovation In Congress

Allergan CEO Brent Saunders, speaking at the BIO International Convention on June 19, said the biopharma industry needs to improve its image before its defenders in Congress bow to public pressure on drug pricing concerns.

Pricing Debate Leadership
See All
UsernamePublicRestriction

Register